Jubiant Therapeutics gets USFDA clearance for JBI-802 to treat solid tumours
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
The transaction is expected to close in the first quarter of 2022
Hitz shall assume new role from January 17th, 2022
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
After double lung transplantation, he was discharged without supplemental oxygen on the eleventh day
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies
It is the generic version of molnupiravir
Entacapone tablets USP, 200 mg have an estimated market size of US$ 10.5 million for twelve months ending September 2021, according to IQVIA
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
Subscribe To Our Newsletter & Stay Updated